全文获取类型
收费全文 | 14732篇 |
免费 | 968篇 |
国内免费 | 51篇 |
专业分类
耳鼻咽喉 | 96篇 |
儿科学 | 512篇 |
妇产科学 | 471篇 |
基础医学 | 1870篇 |
口腔科学 | 218篇 |
临床医学 | 2098篇 |
内科学 | 2652篇 |
皮肤病学 | 276篇 |
神经病学 | 1585篇 |
特种医学 | 301篇 |
外科学 | 1300篇 |
综合类 | 122篇 |
现状与发展 | 1篇 |
一般理论 | 16篇 |
预防医学 | 2028篇 |
眼科学 | 335篇 |
药学 | 948篇 |
中国医学 | 15篇 |
肿瘤学 | 907篇 |
出版年
2023年 | 93篇 |
2022年 | 153篇 |
2021年 | 348篇 |
2020年 | 199篇 |
2019年 | 363篇 |
2018年 | 417篇 |
2017年 | 273篇 |
2016年 | 318篇 |
2015年 | 388篇 |
2014年 | 516篇 |
2013年 | 791篇 |
2012年 | 1103篇 |
2011年 | 1172篇 |
2010年 | 641篇 |
2009年 | 521篇 |
2008年 | 1037篇 |
2007年 | 1045篇 |
2006年 | 1047篇 |
2005年 | 1019篇 |
2004年 | 953篇 |
2003年 | 907篇 |
2002年 | 863篇 |
2001年 | 97篇 |
2000年 | 70篇 |
1999年 | 101篇 |
1998年 | 142篇 |
1997年 | 134篇 |
1996年 | 124篇 |
1995年 | 121篇 |
1994年 | 68篇 |
1993年 | 91篇 |
1992年 | 59篇 |
1991年 | 54篇 |
1990年 | 46篇 |
1989年 | 40篇 |
1988年 | 48篇 |
1987年 | 31篇 |
1986年 | 31篇 |
1985年 | 31篇 |
1984年 | 45篇 |
1983年 | 38篇 |
1982年 | 45篇 |
1981年 | 44篇 |
1980年 | 33篇 |
1979年 | 13篇 |
1978年 | 18篇 |
1977年 | 9篇 |
1976年 | 8篇 |
1973年 | 6篇 |
1972年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
171.
172.
Ziwei Yu Paul M Weinberger Bruce G Haffty Clarence Sasaki Cynthia Zerillo John Joe Diane Kowalski James Dziura Robert L Camp David L Rimm Amanda Psyrri 《Clinical cancer research》2005,11(3):1160-1166
BACKGROUND: The current tumor-node-metastasis system is inadequate to accurately classify patients in terms of prognosis. Thus, with the availability of recently developed molecular tools, considerable interest lies in discovering prognostic markers in order to guide treatment decisions. In this study, we sought to determine the prognostic significance of the cell cycle regulator cyclin D1 in oropharyngeal squamous cell carcinoma (OSCC). EXPERIMENTAL DESIGN: We studied the protein expression levels of cyclin D1 on a tissue microarray composed of 63 OSCCs with long-term follow-up data available. Protein expression was analyzed with an automated in situ quantitative (AQUA) method which allows preservation of tissue morphology while quantifying protein expression in paraffin-embedded tissue. RESULTS: The mean follow-up time was 35 months. High cyclin D1 nuclear expression was associated with increased 5-year local recurrence rate (48% versus 15%), inferior 5-year disease-free survival (16% versus 58%), and inferior 5-year overall survival (17% versus 53%). In multivariate Cox regression, high nuclear cyclin D1 expression was an independent predictor for local recurrence, disease-free survival, and overall survival at 5 years. CONCLUSIONS: Our results indicate that quantitative assessment of nuclear cyclin D1 expression level by automated in situ quantitative analysis is a strong predictor for outcome in OSCC. Thus, cyclin D1 may be a potential target for molecular intervention in patients with oropharyngeal squamous cell cancer. 相似文献
173.
Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. 总被引:1,自引:0,他引:1
Cynthia X Ma Suresh Nair Sachdev Thomas Sumithra J Mandrekar Daniel A Nikcevich Kendrith M Rowland Tom R Fitch Harold E Windschitl Shauna L Hillman Steven E Schild James R Jett Coleman Obasaju Alex A Adjei 《Journal of clinical oncology》2005,23(25):5929-5937
PURPOSE: A randomized three-arm phase II study was undertaken to evaluate the optimum administration schedule of pemetrexed and gemcitabine in chemotherapy-na?ve patients with non-small-cell lung cancer. PATIENTS AND METHODS: Patients were randomly assigned to three schedules of pemetrexed 500 mg/m2 plus gemcitabine 1,250 mg/m2, separated by a 90-minute interval, on a 21-day cycle as follows: schedule A, pemetrexed followed by gemcitabine on day 1 and gemcitabine on day 8; schedule B, gemcitabine followed by pemetrexed on day 1 and gemcitabine on day 8; and schedule C, gemcitabine on day 1 and pemetrexed followed by gemcitabine on day 8. RESULTS: One hundred fifty-two eligible patients (schedule A, n = 59; schedule B, n = 31, and schedule C, n = 62) received a median of five (schedule A), two (schedule B), and four (schedule C) treatment cycles. Overall, 66% of patients experienced grade 3 or 4 neutropenia. Common grade 3 and 4 nonhematologic toxicities were dyspnea (11%), fatigue (16%), and transaminase elevation (9%). Schedule A seemed less toxic compared with schedule C (grade 3 or 4 events: 86% v 94%, respectively; P = .19; grade 4 events: 39% v 48%, respectively; P = .30). Schedule B was closed at interim analysis for inferior efficacy. Schedule A, with a confirmed response rate of 31% (95% CI, 20% to 45%), met the protocol-defined efficacy criteria, whereas schedule C, with a confirmed response rate of 16.1% (95% CI, 11% to 34%), did not. Median survival time and time to progression were 11.4 and 4.4 months, respectively, with no observable difference between the arms. CONCLUSION: Pemetrexed and gemcitabine administered as outlined for schedule A met the protocol-defined efficacy criteria, was less toxic compared with the other treatment schedules, and should be further evaluated. 相似文献
174.
Donna L Forrest Donna E Hogge Thomas J Nevill Stephen H Nantel Michael J Barnett John D Shepherd Heather J Sutherland Cynthia L Toze Clayton A Smith Julye C Lavoie Kevin W Song Nicholas J Voss Randy D Gascoyne Joseph M Connors 《Journal of clinical oncology》2005,23(31):7994-8002
PURPOSE: To determine the incidence of second malignancies among patients with Hodgkin's lymphoma (HL) treated with autologous hematopoietic stem cell transplantation (AHSCT) compared with patients receiving conventional therapy alone and to identify potential risk factors for their occurrence. PATIENTS AND METHODS: We analyzed data on 1,732 consecutive patients with HL treated at the British Columbia Cancer Agency from 1976 to 2001, including 202 patients undergoing AHSCT. The median follow-up duration was 9.8 years for the whole cohort, 9.7 years for those patients treated with conventional therapy, and 7.8 years from AHSCT. RESULTS: The cumulative incidence of developing any second malignancy 15 years after therapy for HL was 9% (risk ratio = 3.5; P < .001); however, the incidence did not differ between those patients receiving conventional therapy alone compared with those undergoing AHSCT (10% and 8%, respectively; P = .48). In multivariate analysis, the only factor significantly associated with an increased risk of developing any second neoplasm or solid tumor was age > or = 35 years (P < .0001). An increased risk of therapy-induced acute myeloid leukemia and therapy-induced myelodysplastic syndrome was seen for patients aged > or = 35 years (P = .03) and stage III/IV (P = .04). CONCLUSION: Patients with HL are at increased risk of developing a second neoplasm. However, those patients undergoing AHSCT do not seem to be at greater risk compared with those patients receiving conventional therapy alone, at least during the first decade after therapy. 相似文献
175.
Cynthia Marie-Claire Cindie Courtin Bernard P Roques Florence Noble 《Neuropsychopharmacology》2004,29(12):2208-2215
It has been previously suggested that morphine can regulate the expression and function of some proteins of the cytoskeleton. In the present study, we used real-time quantitative polymerase chain reaction to examine the effects of chronic morphine administration, in rat striatum, on 14 proteins involved in microtubule polymerization and stabilization, intracellular trafficking, and serving as markers of neuronal growth and degeneration. Chronic morphine treatment led to modulation of the mRNA level of seven of the 14 genes tested. Glial fibrillary acidic protein (Gfap) and activity-regulated cytoskeleton-associated protein (Arc) mRNA were upregulated, while growth associated protein (Gap43), clathrin heavy chain (Cltc), alpha-tubulin, Tau, and stathmin were downregulated. In order to determine if the regulation of an mRNA correlates with a modulation of the expression of the corresponding protein, immunoblot analyses were performed. With the exception of Gap43, the levels of Cltc, Gfap, Tau, stathmin, and alpha-tubulin proteins were found to be in good agreement with those from mRNA quantification. These results demonstrate that neuroadaptation to chronic morphine administration in rat striatum implies modifications of the expression pattern of several genes and proteins of the cytoskeleton and cytoskeleton-associated components. 相似文献
176.
177.
Nocturnal activation of melatonin receptor type 1 signaling modulates diurnal insulin sensitivity via regulation of PI3K activity
下载免费PDF全文
![点击此处可从《Journal of pineal research》网站下载免费的PDF全文](/ch/ext_images/free.gif)
178.
179.
180.